Despite currently available treatments for lymphoma and multiple myeloma, many patients experience a relapse of their disease. Doctors are therefore seeking more effective therapies. The purpose of this study is to evaluate the combination of two currently available therapies — romidepsin and lenalidomide — in patients with lymphoma or multiple myeloma that has returned or persisted despite prior therapy.
Romidepsin is a drug that is approved to treat cutaneous T-cell lymphoma in patients who have already received a regimen of prior therapy. Lenalidomide is approved for treating multiple myeloma and myelodysplastic syndromes. This study marks the first time these two drugs will be evaluated together.